NETRIS Pharma Secures €7.25 Million In Horizon Europe Funding To Advance Phase 2B Clinical Trial In Head And Neck Cancer

(MENAFN - EIN Presswire) EINPresswire / -- NETRIS Pharma, a clinical-stage oncology company targeting the netrin-1 / epithelial-to-mesenchymal transition (EMT) axis, today announced that it has ...